Literature DB >> 12473243

alpha4 integrins and L-selectin differently orchestrate T-cell activity during diabetes prevention following oral administration of CTB-insulin.

Caroline Aspord1, Cecil Czerkinsky, Annie Durand, Anne Stefanutti, Charles Thivolet.   

Abstract

Oral administration of insulin conjugated to the B chain of cholera toxin (CTB-insulin) in non-obese diabetic (NOD) mice results in diabetes prevention. We investigated the respective contributions of L-selectin (CD62L) and alpha4-integrin pathways during CTB-driven tolerance. Purified CD62L+CD4+ cells from CTB-insulin fed mice significantly reduced the capacity of diabetogenic T cells to transfer diabetes in syngeneic recipients. In vivo antibody blockade of fed animals during adoptive co-transfer experiments indicated that both CD62L and alpha4-integrins pathways were necessary to develop a protective response after oral tolerance induction. In contrast, when antibodies were given to recipient mice, only CD62L was critical for the protection. In vitro stimulated CD62L+CD4+ cells from the spleen of fed animals secreted lower amounts of IL-4 and IL-10 but comparable levels of TGFbeta than CD62L-cells. A reduced IFN-gamma production between the two cell subsets was specifically observed in CTB-insulin fed mice. Furthermore, antibody treatments induced changes in T-cell migration to the spleen, mesenteric and pancreatic lymph nodes. The protective effect was also associated with migration of regulatory T cells into pancreatic islets. Taken together, our results suggest that L-selectin and alpha4-integrin have distinct but complementary roles in the generation and function of regulatory CD4+ T cells following CTB-insulin administration.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12473243     DOI: 10.1006/jaut.2002.0610

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  9 in total

1.  The CXCR4/CXCL12 (SDF-1) signalling pathway protects non-obese diabetic mouse from autoimmune diabetes.

Authors:  E Aboumrad; A M Madec; C Thivolet
Journal:  Clin Exp Immunol       Date:  2007-03-21       Impact factor: 4.330

Review 2.  Heat-labile enterotoxins as adjuvants or anti-inflammatory agents.

Authors:  Shuang Liang; George Hajishengallis
Journal:  Immunol Invest       Date:  2010       Impact factor: 3.657

3.  Treg cells in pancreatic lymph nodes: the possible role in diabetogenesis and β cell regeneration in a T1D model.

Authors:  Benjamin K Nti; Janet L Markman; Suzanne Bertera; Alexis J Styche; Robert J Lakomy; Vladimir M Subbotin; Massimo Trucco; Tatiana D Zorina
Journal:  Cell Mol Immunol       Date:  2012-10-08       Impact factor: 11.530

4.  Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells.

Authors:  A M Madec; R Mallone; G Afonso; E Abou Mrad; A Mesnier; A Eljaafari; C Thivolet
Journal:  Diabetologia       Date:  2009-05-07       Impact factor: 10.122

Review 5.  Oral tolerance.

Authors:  Henry Yim Wu; Howard L Weiner
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

6.  Cholera toxin subunit B peptide fusion proteins reveal impaired oral tolerance induction in diabetes-prone but not in diabetes-resistant mice.

Authors:  Maximiliano Presa; Angela Zarama Ortiz; Nahir Garabatos; Cristina Izquierdo; Elisa I Rivas; Luc Teyton; Conchi Mora; David Serreze; Thomas Stratmann
Journal:  Eur J Immunol       Date:  2013-08-27       Impact factor: 5.532

Review 7.  Cholera Toxin Subunit B as Adjuvant--An Accelerator in Protective Immunity and a Break in Autoimmunity.

Authors:  Thomas Stratmann
Journal:  Vaccines (Basel)       Date:  2015-07-24

Review 8.  Therapeutic Potential of Cholera Toxin B Subunit for the Treatment of Inflammatory Diseases of the Mucosa.

Authors:  Joshua M Royal; Nobuyuki Matoba
Journal:  Toxins (Basel)       Date:  2017-11-23       Impact factor: 4.546

Review 9.  Mucosal exposure to antigen: cause or cure of type 1 diabetes?

Authors:  Georgia Fousteri; Matthias von Herrath; Damien Bresson
Journal:  Curr Diab Rep       Date:  2007-04       Impact factor: 5.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.